Survival of biological therapeutics in psoriasis : retrospective analysis of 3-years data in a Turkish registry, PSORTAKSIS
BACKGROUND: TPSORTAKSIS is a psoriasis registry, which is used for follow-up of patients in Kayseri City Education and Research Hospital, Dermatology Clinic since 2016 in Turkey. PSORTAKSIS includes demographic data, follow-up clinical findings, laboratory output, and treatment information of patients. Here, drug survivals of biologic therapeutics (BT) according to three-year data of PSORTAKSIS will be presented.
METHODS: Drug survival of BT in PSORTAKSIS was analyzed from 2016 to March 2019.
RESULTS: 158 patients (111 of them BT-naive) with psoriasis under BT were enrolled in the current study. Drug survival analysis of patients with ongoing BT (158 treatment periods) revealed mean survival time as 15.49 months for ustekinumab, 15.37 months for adalimumab, 14.00 months for etanercept, 5 months for infliximab, and 4.59 months for secukinumab. The differences between drug survivals of BT were statistically significant (log-rank test, χ2 = 79.915, p < 0.0001).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:52 |
|---|---|
| Enthalten in: |
Turkish journal of medical sciences - 52(2022), 1 vom: 13. Feb., Seite 58-66 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Özyurt, Kemal [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-TNF |
|---|
| Anmerkungen: |
Date Completed 01.12.2022 Date Revised 23.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3906/sag-2104-339 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329099388 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329099388 | ||
| 003 | DE-627 | ||
| 005 | 20231227140251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3906/sag-2104-339 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1236.xml |
| 035 | |a (DE-627)NLM329099388 | ||
| 035 | |a (NLM)34365780 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Özyurt, Kemal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Survival of biological therapeutics in psoriasis |b retrospective analysis of 3-years data in a Turkish registry, PSORTAKSIS |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.12.2022 | ||
| 500 | |a Date Revised 23.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: TPSORTAKSIS is a psoriasis registry, which is used for follow-up of patients in Kayseri City Education and Research Hospital, Dermatology Clinic since 2016 in Turkey. PSORTAKSIS includes demographic data, follow-up clinical findings, laboratory output, and treatment information of patients. Here, drug survivals of biologic therapeutics (BT) according to three-year data of PSORTAKSIS will be presented | ||
| 520 | |a METHODS: Drug survival of BT in PSORTAKSIS was analyzed from 2016 to March 2019 | ||
| 520 | |a RESULTS: 158 patients (111 of them BT-naive) with psoriasis under BT were enrolled in the current study. Drug survival analysis of patients with ongoing BT (158 treatment periods) revealed mean survival time as 15.49 months for ustekinumab, 15.37 months for adalimumab, 14.00 months for etanercept, 5 months for infliximab, and 4.59 months for secukinumab. The differences between drug survivals of BT were statistically significant (log-rank test, χ2 = 79.915, p < 0.0001) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a psoriasis registry | |
| 650 | 4 | |a Psoriasis | |
| 650 | 4 | |a anti-TNF | |
| 650 | 4 | |a drug survival | |
| 650 | 4 | |a secukinumab | |
| 650 | 4 | |a ustekinumab | |
| 650 | 7 | |a Ustekinumab |2 NLM | |
| 650 | 7 | |a FU77B4U5Z0 |2 NLM | |
| 700 | 1 | |a Zararsız, Gökmen |e verfasserin |4 aut | |
| 700 | 1 | |a Ertaş, Ragıp |e verfasserin |4 aut | |
| 700 | 1 | |a Cephe, Ahu |e verfasserin |4 aut | |
| 700 | 1 | |a Kutlu, Ömer |e verfasserin |4 aut | |
| 700 | 1 | |a Elmas, Ömer Faruk |e verfasserin |4 aut | |
| 700 | 1 | |a Akkuş, Muhammed Reşat |e verfasserin |4 aut | |
| 700 | 1 | |a Kutlu, Fatma Nur |e verfasserin |4 aut | |
| 700 | 1 | |a Atasoy, Mustafa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Turkish journal of medical sciences |d 1997 |g 52(2022), 1 vom: 13. Feb., Seite 58-66 |w (DE-627)NLM093849745 |x 1303-6165 |7 nnns |
| 773 | 1 | 8 | |g volume:52 |g year:2022 |g number:1 |g day:13 |g month:02 |g pages:58-66 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3906/sag-2104-339 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 52 |j 2022 |e 1 |b 13 |c 02 |h 58-66 | ||